Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
30.06.25 | 19:23
0,745 Euro
+6,58 % +0,046
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6940,71620:04
0,6940,71519:58

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAtossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline12
06.06.Ascendiant Capital raises Atossa Genetics stock price target to $7.5023
05.06.Atossa Therapeutics bei Jefferies-Konferenz: Strategische Schritte gegen Brustkrebs30
20.05.Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22355SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines...
► Artikel lesen
14.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen268Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics...
► Artikel lesen
13.05.Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.016
13.05.ATOSSA THERAPEUTICS, INC. - 10-Q, Quarterly Report3
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
13.05.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report1
13.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update199Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new...
► Artikel lesen
05.05.RedChip Companies, Inc.: Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV333ORLANDO, FL / ACCESS Newswire / May 5, 2025 / RedChip Companies aired interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Money show...
► Artikel lesen
30.04.Atossa wins U.S. patent related to multiple formulation of lead asset5
30.04.Atossa Therapeutics secures new patent for breast cancer drug7
30.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio168SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
29.04.Atossa stellt Phase-3-Studie zur Brustkrebsprävention vor11
29.04.Atossa outlines phase 3 trial for breast cancer prevention2
29.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025204SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
22.04.Atossa Therapeutics sichert neues Patent für Brustkrebsbehandlung30
22.04.Atossa Therapeutics secures new patent for breast cancer treatment4
22.04.Atossa Therapeutics announces issuance of U.S. patent3
22.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio225SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,11